151 related articles for article (PubMed ID: 31949329)
1. Determination of urokinase-type plasminogen activator serum levels in healthy and oncologic cats.
Viegas C; de Matos AJ; Leite-Martins LR; Viegas I; Ferreira RRF; Gregório H; Santos AA
Can J Vet Res; 2020 Jan; 84(1):60-66. PubMed ID: 31949329
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.
Ramos SC; de Matos AJ; Ribeiro JN; Leite-Martins LR; Ferreira RRF; Viegas I; Santos AA
Vet World; 2017 Aug; 10(8):918-923. PubMed ID: 28919683
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
4. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
Banys-Paluchowski M; Witzel I; Aktas B; Fasching PA; Hartkopf A; Janni W; Kasimir-Bauer S; Pantel K; Schön G; Rack B; Riethdorf S; Solomayer EF; Fehm T; Müller V
Sci Rep; 2019 Feb; 9(1):2318. PubMed ID: 30783124
[TBL] [Abstract][Full Text] [Related]
5. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Eur J Cancer; 1998 Jul; 34(8):1193-7. PubMed ID: 9849478
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
10. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
11. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
12. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Itoh T; Hayashi Y; Kanamaru T; Morita Y; Suzuki S; Wang W; Zhou L; Rui JA; Yamamoto M; Kuroda Y; Itoh H
J Gastroenterol Hepatol; 2000 Apr; 15(4):422-30. PubMed ID: 10824888
[TBL] [Abstract][Full Text] [Related]
15. Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.
Pedersen AN; Brünner N; Høyer-Hansen G; Hamer P; Jarosz D; Larsen B; Nielsen HJ; Stephens RW
Clin Chem; 1999 Aug; 45(8 Pt 1):1206-13. PubMed ID: 10430786
[TBL] [Abstract][Full Text] [Related]
16. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
17. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
18. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
Cobos E; Jumper C; Lox C
Clin Appl Thromb Hemost; 2003 Jul; 9(3):241-6. PubMed ID: 14507113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
